2021 PDA Innovations in Vaccines Conference
Registration Options
Individual Registration
Group Registration
On behalf of the Program Planning Committee and PDA, we would like to invite you to the 2021 PDA Innovations in Vaccines Conference on 08-09 June 2021. The agenda will focus on the theme of “Manufacturing. Technology. Supply.” This conference will provide a platform to present and discuss new developments in Vaccines & Cold Chain.
On day one we plan to focus on the vaccine landscape, control strategies & host a panel discussion focused on challenges in cold chain. On day two we plan to discuss PDA Vaccine activities, Supply Chain & host a regulatory panel discussion.
We anticipate a strong agenda of knowledgeable experts in this field along with an exciting virtual exhibition of the latest commercial inspection technology and services. If you are interested in exhibiting please contact David Hall.
We look forward to seeing you online for the 2021 PDA Innovations in Vaccines Conference!
Program Planning Committee
Cristiana Campa, GSK Vaccines
Jane Halpern, Consultant
Nina Heinz, DHL (co-chair)
Sabrina Restrepo, Merck
(co-chair)
Register Early and SAVE!
At the completion of this meeting, participants will be able to:
- Discuss lessons learned in vaccine development due to the pandemic to apply in future instances
- Identify how to enable accelerated development, including risk- based strategies and technical innovations
- Articulate the importance of vaccine logistics through perspectives about the challenges encountered in the transportation of temperature sensitive vaccine shipments
Contact
Program Inquiries
Exhibition/Sponsorship Inquiries
Training Course Inquiries
Registration Customer Care
Standard Pricing
Standard Member Price
$800GovernmentMember Only
$435
Health AuthorityMember Only
$435
Early Career ProfessionalMember Only
$475
StudentMember Only
$265
AcademicMember Only
$435
Non-Member
$915
GROUP REGISTRATION DISCOUNT: Register 3 people from the same organization as a group (at the same time) for the event and receive the 4th registration free. Other discounts cannot be applied.
GENERAL TERMS AND CONDITIONS: PDA will send you a confirmation letter within one week of payment being received. You must have this confirmation letter to be considered enrolled in a PDA event. If you have submitted a purchase order or requested an invoice, please be advised that a credit card guarantee is needed. PDA reserves the right to modify the material or speakers/trainers without notice or to cancel an event. If an event is cancelled, registrants will be notified by PDA immediately and will receive a credit (registration fee paid). PDA will not be responsible for any costs incurred by registrants due to cancellation. Please note that the attendee list is shared with attendees, trainers, and exhibitors and may be used to follow up on specific areas of interest after the event. Video, photo, and audio recordings are prohibited at all PDA events.
CANCELLATION: If a cancellation request is received 30 days before the event, a credit (registration fee paid minus a 200.00 USD/EUR processing fee) will be given. No credits will be given for cancellation requests received less than 30 days before the event. Cancellation requests must be emailed to [email protected].
Day 1
Tuesday, 08 June
|
09:00 – 10:10 | Plenary 1: How COVID Changed the Vaccine Landscape The urgent response driven by the COVID-19 pandemic brought the need for speed in the vaccine development space as well as the sense for collaboration among all the relevant stakeholders. In addition, forced us to: open the barriers to new technologies, or accelerate development by leveraging prior knowledge and/or existing platforms; educate more the general public about vaccines so herd immunity can be achieved faster; worked together as a village (suppliers, drug manufacturers, governments, regulatory agencies, patients) to enable production at higher levels for a worldwide coverage; and lastly, teach us more lessons to better prepare us for next pandemic. This session will present some of those lessons learned during this pandemic. |
|
09:00 - 09:10 | Welcome from the Program Planning Committee Co-Chair 09:10 - 09:30 | Lessons Learned 09:30 - 09:50 |
Cross Company Learnings and Discussion with Vaccines 09:50 - 10:10 | Q&A Panel Discussion |
10:10 – 10:40 | Break & Extended Q&A
|
10:40 – 11:40 | Plenary 2: Control Strategies This session will provide insights on advanced control strategies for vaccines development and lifecycle, taking into account product, process and analytical considerations. In this context, reflections on how to enable accelerated development will be discussed, including risk- based strategies and technical innovations. Examples will include use of prior knowledge, tech transfer, testing and stability strategies, considering novel and established vaccine platforms, with learnings from COVID-19 health emergency. |
|
10:40 - 11:00 | Quality by Digital Design to Support Rapid RNA Vaccine Production Against Emerging Infectious Diseases 11:00 - 11:20 | Enabling Accelerated Development - Patient Centric Specifications and Stability 11:20 - 11:40 | Q&A Panel Discussion |
11:40 – 12:30 | Break & Extended Q&A
|
12:30 – 13:30 | Plenary 3: Panel Discussion - Supply/Cold Chain Challenges This session will discuss the supply and cold chain challenges as they relate to vaccine distribution and administration. |
|
Panel
|
Day 2
Wednesday, 09 June
|
09:00 – 10:10 | Plenary 4: PDA Vaccine Activities The PDA Vaccine Task Force and PDA Vaccine Interest Group have multiple activities planned for 2021 and beyond. These includes publications as well as webinars and meetings on topics of interest for both novel vaccines and more traditional products. This session will provide an overview of current activities and areas for volunteering from interested members. |
| 09:00 - 09:20 | Vaccines IG Update Jane Halpern, Consultant 09:20 - 09:40 | Current PDA Vaccine Initiatives and Volunteer Opportunities Stephan Krause, PhD, Director, Product Quality, AstraZeneca 09:40 - 10:00 | Q&A Panel Discussion |
10:10 – 10:40 | Break & Extended Q&A
|
10:40 – 11:40 | Plenary 5: Supply Chain for Temperature Sensitive Products The Covid-19 pandemic has brought to the forefront many of the challenges encountered in the transportation of temperature sensitive vaccine shipments across the globe. This includes managing multiple supply chain partners, airfreight capacity restrictions, changing government regulations, new ultra-low temperature ranges and may other factors. |
| 10:30 - 10:50 | Where to Reduce E2E Distribution Costs? Fabian de Paoli, CCM28 10:50 - 11:10 | Supply Chain for Temperature Sensitive Products Richard Peck, AstraZeneca 11:10 - 11:30 | Q&A Panel Discussion |
11:40 – 12:30 | Break & Extended Q&A
|
12:30 – 13:30 | Plenary 6: Panel Discussion - The Regulatory Lessons from COVID-19 Industry and National Health Authorities will talk about the regulatory lessons learned during this pandemic regarding post-approval changes, harmonization, reliance/recognition and COVAX efforts that have enabled an accelerated approval of the emergency use for several vaccine candidates, as well as the challenges ahead for pursuing licensure of these vaccines. In addition, perspectives about how to further enable vaccine modernization in the future based on COVID lessons would be discussed. |
|
Panel
|
Become a Sponsor
Interested in becoming a sponsor? Learn about opportunities and benefits.
Request InformationBecome an Exhibitor
Interested in becoming an exhibitor? Learn about opportunities and benefits.
Request InformationPLEASE READ PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.